Executive readout · one minute
What the filings say
- 8-K earnings release · filed Nov 5, 2026
- Starling Oncology reported third-quarter revenue of $169.8 million, up 24.3% year over year, and Adjusted EBITDA of positive $3.4 million. It updated fiscal-year 2026 revenue guidance to $650 to $660 million and Adjusted EBITDA guidance to $4 to $6 million.
- 10-Q report · filed Nov 6, 2026
- Starling Oncology reported third-quarter revenue of $169,767 and net loss of $(15,748), with figures in thousands; Adjusted EBITDA was $3,394. At September 30, 2026, cash was $36,895, and management expected liquidity for at least one year.
The audio replay and transcript follow the call.